ABSTRACTS POSTER SESSION Archives - Page 3 of 6

P.06 THE IMPACT OF NETWERK ON THE MULTIDISCIPLINARY TUMOR BOARDS

BJMO - 12, issue 3, february 2018

T. Vandamme MD, W. Lybaert MD, M. Simoens , W. Demey MD, T. Rondou , P. Abrams , C. Mattelaer , B. Op De Beeck , O. D’Archambeau , G. Roeyen , L. De Backer , Marc Peeters , Steering Committee , NET-specialists

P.05 LONG-TERM CLINICAL OUTCOME AND SURVIVORSHIP ISSUES OF HIGH GRADE BONE SARCOMAS

BJMO - 12, issue 3, february 2018

C. Closset , T. Gil MD, Martine Piccart , M.J. Piccart-Gebhart MD

P.04 ENDOTHELIAL CELL METABOLISM BLOCKADE TO INDUCE TUMOR VESSEL NORMALIZATION AND IMPROVE CURRENT IMMUNOTHERAPY

BJMO - 12, issue 3, february 2018

V. Geldhof , A.R. Cantelmo , P. Carmeliet

P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY

BJMO - 12, issue 3, february 2018

B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , J. Go , M. Collins , T. Golsorkhi , W. Abida , C. Ryan , H. Scher , S. Chowdhury

P.02 THE ROLE OF TOPOISOMERASE II-A (TOPO IIA) AS A PREDICTIVE FACTOR FOR RESPONSE TO NEOADJUVANT ANTHRACYCLINES BASED CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER

BJMO - 12, issue 3, february 2018

M. Gamea

P.01 A LUNG CANCER-DERIVED CRAF MUTATION IS ERK PATHWAY ACTIVATING AND PREDICTS SENSITIVITY TO COMBINED TYPE II RAF AND MEK INHIBITION

BJMO - 12, issue 3, february 2018

A. Noeparast PhD, J. De Grève MD, PhD, S. De Brakeleer PhD, P. Giron , C. Eggermont , R.B. Shahi MSc, E. Teugels PhD

P.10 Systemic treatment preferences for patients with advanced desmoid-type fibromatosis (DF) in Europe

BJMO - 2017, issue 3, february 2017

T. Van Cann , A. Requilé , P. Schöffski MD